CMPX Stock Forecast: Compass Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$0.68
+11.05% on the day

The median 12-month analyst price target for Compass Therapeutics, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$122.2M
Ticker Nerd rank
29/ 100
Median analyst target
$4.00
Analysts covering
15
Revenue$0.0
Operating income−$27.0M
Net income−$25.2M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.3%
1M
−18.7%
YTD
−87.4%
1Y
−86.2%
From 52W high
−89.9%
From 52W low
+11.8%
$0.61
$6.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Compass Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Quality
55
Issuance
51
Volatility
40
Growth
33
Value
32
Revisions
23
Momentum
7

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CMPX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMPX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26CMPXHigh $12.00Median $4.00Low $0.90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
12
Buy
3
Hold
0
Sell
$0.90
Low
$4.00
Median
$12.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
10 Nov 2026WedbushMaintainsNeutral$1.00 → $0.90
23 Sept 2026CitizensMaintainsMarket Outperform$10 → $4.00
23 Sept 2026Craig-HallumMaintainsBuy$15 → $8.00
23 Sept 2026GuggenheimMaintainsBuy$8.00 → $4.00
23 Sept 2026HC Wainwright & Co.MaintainsBuy$24 → $12
23 Sept 2026WedbushDowngradeNeutral$5.00 → $1.00
7 Aug 2026Piper SandlerMaintainsOverweight$4.00 → $6.00
28 Apr 2026Canaccord GenuityMaintainsBuy$13 → $7.00
28 Apr 2026CitizensReiteratesMarket Outperform$10
27 Apr 2026D. Boral CapitalMaintainsBuy$30
27 Apr 2026HC Wainwright & Co.ReiteratesBuy$24
24 Mar 2026GuggenheimReiteratesBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026William BlairInitiatesOutperform—
3 Dec 2025Canaccord GenuityInitiatesBuy—
3 Dec 2025Cantor FitzgeraldInitiatesOverweight—
3 Dec 2025CitizensInitiatesMarket Outperform—
5 Nov 2025D. Boral CapitalMaintainsBuy—
6 Oct 2025LifeSci CapitalInitiatesOutperform—
12 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CMPX.

Market Radar

This page is one stock. Monday covers all of them.

CMPX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CMPX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Compass Therapeutics, Inc. returned −86.2% against +9.2% for the S&P 500, dividends included.

CMPX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26CMPXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CMPX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.9×

Cheaper than 77% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−49.0%

Higher than 22% of US stocks

Return on assets
−29.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Compass Therapeutics, Inc. has a market value of $122.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$73.4M.

  • Diluted earnings per share, trailing twelve months: −$0.40.

  • Free cash flow in the twelve months to 30 June 2026: −$56.4M.

  • Shares outstanding: 180.1M.

  • Compass Therapeutics, Inc. employs 39 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CMPX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CMPXCompass Therapeutics, Inc.$122.2M29
CNTNCanton Strategic Holdings, Inc.$109.0M7
NERVMinerva Neurosciences, Inc.$108.6M28
GNLXGenelux Corp.$107.7M14
OKUROnKure Therapeutics, Inc.$113.9M52
UPBUpstream Bio, Inc.$113.9M20
FHTXFoghorn Therapeutics, Inc.$104.9M56

Take a look at CMPX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Compass Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CMPX

What is the CMPX stock price forecast for 2026-2027?

The median 12-month analyst price target for Compass Therapeutics, Inc. is $4, with estimates ranging from $0.9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CMPX stock a buy right now?

Of the 15 analysts covering Compass Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compass Therapeutics, Inc. 29 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CMPX?

As at 18 Nov 2026, Compass Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will CMPX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts is $4, and Ticker Nerd's factor model ranks Compass Therapeutics, Inc. 29 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CMPX stock forecast for 2030?

No analyst covering Compass Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMPX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.9 to $12 over the next 12 months.

How has CMPX stock performed over the past year?

Compass Therapeutics, Inc. returned -86.2% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Compass Therapeutics, Inc. do?

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses.

Company

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.

CEO Dr. Thomas J. Schuetz M.D., Ph.D. · 39 employees · United States · https://www.compasstherapeutics.com